Skip to content

Scientific Publications

Page 'Sub' Navigation:

Page Path 'Breadcrumb':

Presentations

 2011 ACR/ARHP Annual Scientific Meeting

Identification of Specific Amino Acids in the Uric Acid Transporter URAT1 Required for Uricosuric-Mediated Inhibition

Identification of Specific Amino Acids in the Uric Acid Transporter URAT1 Required for Uricosuric-Mediated Inhibition

 2011 American Society of Clinical Oncology Annual Meeting

 Safety, Pharmacokinetics, and Pharmacodynamics Results From a Phase 1 Trial of BAY 86-9766 (RDEA119), a MEK Inhibitor, In Patients with Advanced Cancer

Safety, Pharmacokinetics and Pharmacodynamics Results from a Phase 1 Trial of BAY 86-9766, A MEK Inhibitor in Patients with Advanced Cancer

 Annual European Congress of Rheumatology 2011
Efficacy and Safety of Lesinurad (RDEA594), A Novel Uricosuric Agent, Given in Combination with Allopurinol in Allopurinol-Refractory Gout Patients: Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Lesinurad (RDEA594), A Novel Uricosuric Agent, Given In Combination with Allopurinol in Allopurinol-Refractory Gout Patients: Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study

4th Asia Pacific ISSX Meeting
Lesinurad (RDEA594), A Novel URAT1 Inhibitor, Shows Additive Serum Urate Lowering Effects in Combination with Xanthine Oxidase Inhibitor Febuxostat Lesinurad (RDEA594), A Novel URAT1 Inhibitor, Shows Additive Serum Urate Lowering Effects in Combination with Xanthine Oxidase Inhibitor Febuxostat
RDEA3170, A Potent URAT1 Inhibitor with a Favorable Pharmacokinetic and Toxicity Profile RDEA3170, A Potent URAT1 Inhibitor with a Favorable Pharmacokinetic and Toxicity Profile

Annual European Congress of Rheumatology EULAR 2010
Efficacy and Safety of a Range of Doses of RDEA594, a Novel Uricosuric Agent, as a Single Agent in Hyperuricemic Gout Patients: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Experience Efficacy and Safety of a Range of Doses of RDEA594, a Novel Uricosuric Agent, as a Single Agent in Hyperuricemic Gout Patients: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Experience
RDEA684, a Novel, Potent and Efficacious Inhibitor of Human Urate Transporter, URAT1, with a Favorable Pharmacokinetic Profile, and No Mitochondrial Toxicity RDEA684, a Novel, Potent and Efficacious Inhibitor of Human Urate Transporter, URAT1, with a Favorable Pharmacokinetic Profile, and No Mitochondrial Toxicity

48th Annual ICAAC/IDSA 46th Annual Meeting
RDEA806, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment Naïve HIV Patients RDEA806, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment Naïve HIV Patients

2008 ACR/ARHP Annual Scientific Meeting
MEK Inhibitor RDEA119 Suppresses Inflammatory Cytokine Production Induced by Monosodium Urate Crystals MEK Inhibitor RDEA119 Suppresses Inflammatory Cytokine Production Induced by Monosodium Urate Crystals

XVII International AIDS Conference
Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients

Digestive Disease Week 2008
RDEA119, A Potent and Highly Selective MEK Inhibitor Ameliorates Murine Colitis RDEA119, A Potent and Highly Selective MEK Inhibitor Ameliorates Murine Colitis